Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors.

Temelkova‐Kurktschiev, Theodora; Koehler, Carsta; Leonhardt, W.; Schäper, Frank; Henkel, Elena; Siegert, Gabriele; Hanefeld, Markolf

doi:10.2337/diacare.22.2.333

Cited by 141 publications

(99 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We did not find any significant correlation with IMT other than increased AG and AIx after adjustment for age and sex (Table 3). This is in line with the results of previous studies, in which the associations of traditional cardiovascular risk factors with IMT were weaker and less consistent in diabetic study cohorts than in non-diabetic cohorts [44,45,[63][64][65]. In a subset of study patients, we observed that an increase in the mineralisation scores was associated with an increase in IMT, AG and peripheral and central systolic and pulse pressures.…”

Section: Discussionsupporting

confidence: 81%

“…In a smaller study by Brooks et al in which PWA was used, both AG and AIx were increased in diabetic men but not in diabetic women [43]. Likewise, carotid IMT has consistently been shown to be greater in type 2 diabetic patients than in non-diabetic subjects [44][45][46]. In addition, IMT has correlated with the presence of CVD in type 2 diabetic patients [47].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Increased augmentation of central blood pressure is associated with increases in carotid intima–media thickness in type 2 diabetic patients

et al. 2005

View full text Add to dashboard Cite

Aims/hypothesis: Type 2 diabetes is associated with a two-to seven-fold increase in cardiovascular morbidity and mortality. The aim of this study was to determine the relationships between intima-media thickness (IMT), an established marker of atherosclerosis, large artery function and other determinants of cardiovascular risk in type 2 diabetic patients. Methods: We studied 228 type 2 diabetic patients (75 women, aged 62±2 years [mean± SEM]). Carotid IMT was bilaterally measured using ultrasound technology. Applanation tonometry and pulse wave analysis were used to measure aortic systolic and diastolic blood pressures, central pressure augmentation (AG) and the augmentation index (AIx), a measure of systemic arterial stiffness. Conventional cardiovascular risk factors (lipids, HbA 1 c, smoking and diabetes duration) were also assessed. Results: Women had higher AG and AIx (p<0.0001), despite comparable systolic BP and heart rate in women and men. In women, AG (r=0.39, p<0.001), age (r=0.32, p<0.01), brachial systolic BP (r=0.34, p< 0.01) and aortic systolic BP (r=0.34, p<0.01) correlated with IMT. In men, age (r=0.41, p<0.001), diabetes duration (r=0.25, p<0.01), AG (r=0.22, p<0.01), aortic systolic BP (r=0.21, p<0.01), brachial systolic BP (r=0.21, p<0.01) and body weight (r=0.16, p<0.05) correlated with IMT. In multiple linear regression analyses, AG and aortic systolic BP, but not brachial systolic BP, were age-independent determinants of IMT in men and women. In all patients, increased AG (adjusted for sex, age and heart rate) correlated with longer duration of diabetes, urinary albumin excretion and IMT. Conclusions/interpretation: Measures of central systolic pressure correlate with carotid IMT, independently of age and other risk markers.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Increased augmentation of central blood pressure is associated with increases in carotid intima–media thickness in type 2 diabetic patients

et al. 2005

View full text Add to dashboard Cite

show abstract

“…These results suggest that subclinical disease may have developed before the onset of clinical diabetes, assuming that a high percentage of the participants with IGT will ultimately develop clinical diabetes, which is consistent with other studies. 29 The fasting blood glucose levels were a weak predictor of outcomes in the study. Most of the other traditional cardiovascular risk factors were also not significant predictors of the risk of CVD among the diabetics after adjusting for the extent of subclinical disease.…”

Section: Discussionmentioning

confidence: 99%

Diabetes Mellitus

Kuller

Velentgas

Barzilay

et al. 2000

ATVB

155

View full text Add to dashboard Cite

Abstract-Previously diagnosed diabetes mellitus, newly diagnosed diabetes mellitus, and impaired glucose tolerance are important determinants of the risk of clinical cardiovascular disease (CVD). We have evaluated the relation of patients with subclinical CVD, diabetes, and impaired glucose tolerance and "normal" subjects and the risk of clinical CVD in the Cardiovascular Health Study. Diabetes (1343), impaired glucose tolerance (1433), and normal (2421)

show abstract

“…Indeed, this difference is in the same order of magnitude, or even greater, than those reported in studies comparing subjects of similar age with respect to other polymorphisms [21], or comparing subjects with and without vascular risk factors such as diabetes [22] or low HDL-C [23] with their respective healthy controls. Moreover, prospective studies evaluating the capacity of IMT max to predict cardiovascular events showed that moving from the first to the fifth quintile of internal carotid artery IMT max with four steps of about 0.2 mm on average, the relative risk of cardiovascular events increased fourfold [24].…”

Section: Discussionmentioning

confidence: 61%

Tissue factor gene promoter haplotype associates with carotid intima-media thickness in subjects in cardiovascular risk prevention

et al. 2009

View full text Add to dashboard Cite

a b s t r a c tObjective: Tissue factor (TF), key initiator of coagulation, has been ascribed roles not only in thrombosis but also in atherosclerosis. TF gene promoter haplotypes modulate TF expression, thereby potentially affecting atherosclerosis. The objective of this study was to evaluate functionally relevant TF promoter haplotypes as determinants of carotid intima-media thickness (C-IMT), a marker of atherosclerosis. Methods: The haplotype-tagging TF A-603G polymorphism and C-IMT were determined in 611 subjects referred to cardiovascular risk prevention. Subjects were aged 59.7 (58.1-61.1) years (mean (95% C.I.)), 79% were male, and 74% in secondary prevention with a history of coronary, cerebrovascular, or peripheral atherosclerotic disease. TF plasma levels were measured in 120 subjects. Results: Significant dose-dependent associations were found between A-603G genotype and both IMT max and IMT mean-max after adjusting for potential confounders. IMT values were highest in A/A (n = 173), intermediate in A/G (n = 312) and lowest in G/G (n = 126). IMT max values (average and 95% C.I., in mm) for A/A, A/G and G/G, were 2.22 (2.11-2.34), 2.09 (2.01-2.18) and 2.02 (1.90-2.15), respectively (p trend = 0.019), and IMT mean-max values were 1.28 (1.23-1.32), 1.25 (1.22-1.28) and 1.21 (1.16-1.26), respectively (p trend = 0.041). A significant interaction between A-603G genotype and prevention status was found (p = 0.046 and p = 0.042 for IMT max and IMT mean-max , respectively). TF plasma levels did not differ between genotypes and were not determinants of C-IMT. Conclusion: The haplotype-tagging TF A-603G polymorphism is associated with C-IMT, independently of TF levels in plasma. These findings provide clinical evidence of an involvement of TF in atherosclerosis, in addition to its well-known roles in hemostasis and thrombosis.

show abstract

Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors.

Cited by 141 publications

References 0 publications

Increased augmentation of central blood pressure is associated with increases in carotid intima–media thickness in type 2 diabetic patients

Increased augmentation of central blood pressure is associated with increases in carotid intima–media thickness in type 2 diabetic patients

Diabetes Mellitus

Tissue factor gene promoter haplotype associates with carotid intima-media thickness in subjects in cardiovascular risk prevention

Contact Info

Product

Resources

About